Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk

• 1 Keogh Institute for Medical Research, Perth, WA
• 2 Sir Charles Gairdner Hospital, Perth, WA
• 3 University of Western Australia, Perth, WA

---

• 1. Garvan Institute of Medical Research. Fracture risk calculator. https://www.garvan.org.au/promotions/bone‐fracture‐risk/calculator/ (viewed Feb 2022).
• 2. McClung MR. Cancel the denosumab holiday. Osteoporos Int 2016; 27: 1677–1682.
• 3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–1117.
• 4. Khan AA, Morrison A, Kendler DL, et al. Case‐based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ. J Clin Densitom 2017; 20: 8–24.
• 5. Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011; 142: 1243–1251.
• 6. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75–85.
• 7. McClung MR, Wagman RB, Miller PD, et al. Observations following discontinuation of long‐term denosumab therapy. Osteoporos Int 2017; 28: 1723–1732.
• 8. Lyu H, Yoshida K, Zhao SS, et al. Delayed denosumab injections and fracture risk among patients with osteoporosis : a population‐based cohort study. Ann Intern Med 2020; 173: 516–526.
• 9. Bone Health and Osteoporosis Foundation. Sample letter. http://www.nof.org/wp‐content/uploads/Dear‐Dr‐ONJ‐letter‐FINAL‐FORM1.pdf (viewed Feb 2022).
• 10. Sim IW, Borromeo GL, Tsao C, et al. Teriparatide promotes bone healing in medication‐related osteonecrosis of the jaw: a placebo‐controlled, randomized trial. J Clin Oncol 2020; 38: 2971–2980.
• 11. Neuprez A, Rompen E, Crielaard JM, Reginster JY. Teriparatide therapy for denosumab‐induced osteonecrosis of the jaw in a male osteoporotic patient. Calcif Tissue Int 2014; 95: 94–96.